 CureVac CVAC, 29.47 shares rocketed 26 in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline GSK, 1.28 GSK, -1.38. 